Relapsed and Refractory Multiple Myeloma (RRMM)
Conditions
Keywords
Real-World Outcomes, Multiple Myeloma (MM), Objective response rate (ORR), Triple-class exposed (TCE), Triple-class refractory (TCR), Progression-free survival (PFS), Overall survival (OS)
Brief summary
Primary Objective: 1\. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after meeting the following criteria: (1) have either (a) at least three prior lines (3L) and are triple-class exposed (TCE), or (b) are triple-class refractory (TCR), and (2) meet similar inclusion/exclusion criteria to patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Secondary Objectives: 1. To describe additional outcomes (duration of response \[DOR\], progression-free survival \[PFS\], overall survival \[OS\], and time to next treatment \[TTNT\]) in the same Benchmark Cohort population described in the primary objective. 2. To describe distribution of treatment regimens, ORR, DOR, PFS, OS, and to compare ORR, PFS, OS, and TTNT in an Analysis Cohort consisting of real-world patients derived from the Benchmark Cohort described above who are weighted to align with the characteristics of patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Comparative analyses of PFS and OS will be performed conditional on sufficient maturity of survival data in the R5458-ONC-1826 (NCT03761108) trial at the time of analysis.
Interventions
OTHERNon-Interventional
No study treatment will be administered on this study.
Sponsors
Regeneron Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 at baseline 2. Confirmed diagnosis of active MM by IMWG diagnostic criteria 3. Have myeloma that is response-evaluable with measurable disease by M-protein in serum or urine as specified in the IMWG response criteria. 4. Triple-class exposed or refractory
Exclusion criteria
1. Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis (excluding myeloma-associated amyloidosis), Waldenström macroglobulinemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin (POEMS) changes syndrome 2. Known MM brain lesions or meningeal involvement 3. History of neurodegenerative condition, central nervous system (CNS) movement disorder, or seizure 4. Cardiac ejection fraction \<40% by echocardiogram or multi-gated acquisition scan (MUGA) (or a diagnosis of congestive heart failure, cardiomyopathy, or valvular heart disease as a potential proxy) 5. Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent 6. Live or live attenuated vaccines 7. Treated with B-cell maturation antigen (BCMA)-directed immunotherapies (BCMA antibody-drug conjugates are not excluded). Note: Other protocol-defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients exposed to each type of regimen by line of therapy (LOT) | Up to 6 years | Distribution of treatment regimens |
| Proportion of patients with objective response rate (ORR) | Up to 6 years | Defined as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of response (DOR) | Up to 6 years | Defined as time from the date of the first documented response (best overall response of sCR, CR, VGPR, PR) until the first date of progressive disease (PD) by International Myeloma Working Group (IMWG) or death due to any cause, whichever occurs first. |
| Progression-free survival (PFS) | Up to 6 years | Defined as time from the start of study treatment until the first date of PD by IMWG, or death due to any cause, whichever occurs first. |
| Overall survival (OS) | Up to 6 years | OS is measured from the start of study treatment until death due to any cause. |
| Time to next treatment (TTNT) | Up to 6 years | Defined as time from the start of study treatment until the initiation of the subsequent LOT. |
Countries
United States
Outcome results
None listed